IP Verse

Pharmaceutical Composition Containing An Anti-Nucleating Agent - EP3165220

The patent EP3165220 was granted to Merck Sharp & Dohme on Nov 13, 2024. The application was originally filed on Dec 2, 2005 under application number EP16198994A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3165220

MERCK SHARP & DOHME
Application Number
EP16198994A
Filing Date
Dec 2, 2005
Status
Patent Maintained As Amended
Oct 11, 2024
Grant Date
Nov 13, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBBJan 3, 2020-ADMISSIBLE
KRAUS & LEDERER PARTGMBBDec 17, 2019KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO03035077
OPPOSITIONEP1904067
OPPOSITIONWO03035077
OPPOSITIONWO03086319
OPPOSITIONWO2006060681
OPPOSITIONWO2006060730
OPPOSITIONWO2012147101
SEARCHUS2004002485
SEARCHUS6369094
SEARCHWO0185700
SEARCHWO03035077
SEARCHWO2006060711
SEARCHWO2006060712

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- HAZUDA ET AL., J. VIROL., (1997), vol. 71, pages 7005 - 7011
DESCRIPTION- Remington's Pharmaceutical Sciences, MACK PUBLISHING CO., (1990), pages 1665 - 1675
DESCRIPTION- VACCA ET AL., PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 4096 - 4100
OPPOSITION- BAVIN, "Polymorphism in Process Development", Chemistry & Industry, (19890821), pages 527 - 529
OPPOSITION- BAVIN, "Polymorphism in Process Development", Chemistry & Industry, (19890821), pages 527 - 529, XP001180136
OPPOSITION- GAO et al., "Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations", Drug Dev. Ind. Pharm., (20040000), vol. 30, no. 2, pages 221 - 229
OPPOSITION- GUO et al., "Pharmaceutical applications of naturally occurring water-soluble polymers", Pharm. Sc. Tech. Today, (19980000), vol. 1, no. 6, pages 254 - 261
OPPOSITION- LEUNER ET AL.: "Improving drug solubility for oral delivery using solid dispersion", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 50, 2000, pages 47 - 60, DOI: 10.1016/S0939-6411(00)00076-X
OPPOSITION- M. E. AULTON, "Chapter 20 - Modified-release peroral dosage forms", Pharmaceutics, The Science of Dosage Form Design, (20020000), pages 289 - 305, XP055298170
OPPOSITION- "Pharmaceutics, The Science of Dosage Form Design", 2002, article M. E. AULTON: "Chapter 20 - Modified-release peroral dosage forms", pages: 289 - 305
OPPOSITION- "Polymorphism_( materials_ science", Wikipedia, (20191018), XP055662425
OPPOSITION- RAGHAVAN et al., "Crystallization of hydrocortisone acetate: influence of polymers", International Journal of Pharmaceutics, (20010000), vol. 212, pages 213 - 221
OPPOSITION- USUI et al., "Inhibitory effects of water-soluble polymers on precipitation of RS-8359", Int. J. Pharm., (19970000), vol. 154, pages 59 - 66
OPPOSITION- RAGHAVAN et al., "Crystallization of hydrocortisone acetate: influence of polymers", International Journal of Pharmaceutics, (20010000), vol. 212, pages 213 - 221, XP007915168
OPPOSITION- RAGHAVAN S.L., "Crystallisation of hydrocortisone acetate: influence of polymers", International Journal of Pharmaceutics, (20010000), vol. 212, doi:10.1016/S0378-5173(00)00610-4, pages 213 - 221, XP007915168
OPPOSITION- USUI et al., "Inhibitory effect of water-soluble polymers on precipitation of RS- 8359", International Journal of Pharmaceutics, (19970000), vol. 154, doi:10.1016/S0378-5173(97)00129-4, pages 59 - 66, XP008102782
OPPOSITION- USUI et al., "Inhibitory effects of water-soluble polymers on precipitation of RS-8359", Int. J. Pharm., (19970000), vol. 154, pages 59 - 66, XP008102782
OPPOSITION- LEUNER et al., "Improving drug solubility for oral delivery using solid dispersion", European Journal of Pharmaceutics and Biopharmaceutics, (20000000), vol. 50, doi:10.1016/S0939-6411(00)00076-X, pages 47 - 60, XP004257179
OPPOSITION- GUO et al., "Pharmaceutical applications of naturally occurring water-soluble polymers", Pharm. Sc. Tech. Today, (19980000), vol. 1, no. 6, pages 254 - 261, XP055662415
OPPOSITION- GAO et al., "Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations", Drug Development and Industrial Pharmacy, (20040000), vol. 30, no. 2, pages 221 - 229, XP009115351
OPPOSITION- GAO et al., "Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations", Drug Dev. Ind. Pharm., (20040000), vol. 30, no. 2, pages 221 - 229, XP009115351

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents